FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
This study is a randomized multi-center trial that will assess the effect of adding Selective
Internal Radiation Therapy (SIRT), using SIR-Spheres microspheres®, to a standard
chemotherapy regimen of FOLFOX as first line therapy in patients with non-resectable liver
metastases from primary colorectal adenocarcinoma.
Treatment with the biologic agent bevacizumab, if part of the standard of care at
participating institutions, is allowed within this study at the discretion of the treating
Investigator.